Milestone: Creating Innovative Solutions Milestone Home
 
image thru microscope
Symposia Contact Home

CPSA Digest 2003

From Proteomics to the Pill:
New Initiatives in Proteomics, Drug Discovery, and Development

September 22-24, 2003

CPSA Digest 2003

Day 1: Proceedings | Plenary
Day 2: Proceedings
Day 3: Proceedings

CPSA 2003 Sponsors

CPSA Digest Archive
CPSA Digest 2000
CPSA Digest 2001
CPSA Digest 2002
CPSA Digest 2003 >>
CPSA Digest 2004


Day 1

Vendor Session - Proteomics Technologies & Applications

Reproducible Removal Of Multiple High-Abundant Proteins From Human Serum
With Polyclonal Antibody-Based LC Affinity Column

Kelly Zhang, Nina Zolotarjova, Gordon Nicol, James Martosella,
Liang-Sheng Yang, Cory Szafranski, Jerome Bailey, and Barry Boyes
Agilent Technologies



It is believed that the analysis of serum proteome will provide access to new protein markers that may hold the information needed to revolutionize disease diagnosis and therapeutic monitoring. However, the masking effect of a few well-characterized, high-abundant proteins in serum has been a major obstacle for the detection of low-abundant proteins that may be of interest for biomarker identification. The Agilent Multiple Affinity Removal System combines the specificity of antibody-antigen recognition and the efficiency of standard LC instrumentation. For the first time, a ready-to-use high-abundant protein removal kit containing an affinity column and optimized mobile phases (Buffers A and B) is available for simultaneous removal of multiple proteins from human serum in a single step. The column removes albumin, transferrin, IgG, IgA, haptoglobin and antitrypsin with high specificity and reproducibility. The buffers are optimized to minimize removal of proteins not targeted by the antibodies. As a result, the less-abundant proteins can be resolved with improved visibility using current separation methodologies such as 1DGE, 2DGE and LC systems.


Return to Proceedings »



overview | training | workshops | consulting | symposia | contact | home